Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.
BACKGROUND:Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibit...
Main Authors: | Darrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, Omar Sued, Ana Gun, Rupert Kaul, Janet M Raboud, Leah Szadkowski, Mark W Hull, Sharon L Walmsley, Pedro Cahn, Argentinean GARDEL research network |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0221653 |
Similar Items
-
Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01) -
Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01) -
Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01) -
Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01) -
The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells
by: Rahaba Marima, et al.
Published: (2020-12-01)